Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Registered Report Protocol

Registered Report Protocols describe a study’s rationale and methods for which the planned work was peer-reviewed prior to data collection.

See all article types »

A scoping review protocol on diagnostic strategies to detect occult malignancies in individuals with ischemic stroke

  • Jenneke Leentjens,

    Roles Conceptualization, Formal analysis, Methodology, Project administration, Writing – original draft

    Affiliation Department of Internal Medicine & Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

    ⨯
  • Nicholas L. J. Chornenki,

    Roles Methodology, Software, Writing – review & editing

    Affiliation Internal Medicine Residency Program, Queens University, Kingston, Canada

    ⨯
  • Janneke Spiegelenberg,

    Roles Project administration, Software, Writing – review & editing

    Affiliations Department of Internal Medicine & Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, Synapse Research Institute, Maastricht, The Netherlands

    ⨯
  • Valentina Ly,

    Roles Data curation, Methodology, Project administration, Software, Writing – review & editing

    Affiliation Health Sciences Library, University of Ottawa, Ottawa, Canada

    ⨯
  • Dariush Dowlatshahi,

    Roles Conceptualization, Supervision, Writing – review & editing

    Affiliation Department of Medicine, University of Ottawa, Ottawa, Canada

    ⨯
  • Deborah M. Siegal

    Roles Conceptualization, Methodology, Supervision, Writing – review & editing

    rcarr@toh.ca@debsiegal

    Affiliation Department of Medicine, University of Ottawa, Ottawa, Canada

    ⨯

Abstract

Background

Emerging data show an increased risk of ischemic stroke in patients with a new diagnosis of cancer. As the risk of stroke begins to increase 150 days before cancer is diagnosed, stroke may be the first clinical manifestation of undiagnosed cancer. About 6% of patients with cryptogenic ischemic stroke (unknown etiology after diagnostic evaluations) are diagnosed with cancer within one year. However, the optimal cancer screening strategy in this population is not known. We aim to conduct a scoping review of screening strategies for occult cancer in individuals with ischemic stroke.

Methods

Electronic databases including MEDLINE (Ovid), EMBASE (Ovid), CINAHL (EBSCOhost) and Scopus will be systematically searched to identify articles that report on screening strategies for occult cancer in individuals with ischemic stroke. At least two investigators will independently perform two-stage study selection consisting of title/abstract screening and full-text review, followed by data extraction. Thereafter, a thematic analysis will be conducted to provide an overview of what diagnostic tests/strategies have been used, and their clinical utility in terms of positive and negative predictive value (when available).

Conclusion

We anticipate that the findings of this scoping review will identify strategies used to detect occult cancer in individuals with ischemic stroke and summarize their clinical utility (if reported). Addressing this knowledge gap will help guide the development of future clinical trials on occult cancer screening patients with ischemic stroke.

Citation: Leentjens J, Chornenki NLJ, Spiegelenberg J, Ly V, Dowlatshahi D, Siegal DM (2023) A scoping review protocol on diagnostic strategies to detect occult malignancies in individuals with ischemic stroke. PLoS ONE 18(7): e0289048. https://doi.org/10.1371/journal.pone.0289048

Editor: Fateen Ata, Hamad Medical Corporation, QATAR

Received: September 28, 2022; Accepted: July 5, 2023; Published: July 21, 2023

Copyright: © 2023 Leentjens et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. NLJC and DMS are members of the Canadian Venous Thromboembolism Research Network (CanVECTOR); the Network received grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654). DMS is supported by a Tier 2 Canada Research Chair in Anticoagulant Treatment of Cardiovascular Disease. JL is supported by an ISTH research fellowship.

Competing interests: DMS received honoraria for educational presentations in the last 12 months (paid to institution) from BMS-Pfizer, Roche, and Servier. All other authors have declared that no competing interests exist,

Introduction

Ischemic stroke is a leading cause of disability and mortality worldwide, affecting millions of people [1, 2]. Determining stroke etiology is key for optimal secondary stroke prevention, but remains unidentified in 10% to 40% of patients even after modern diagnostic workup (so-called cryptogenic stroke) [3, 4]. The current definition of cryptogenic stroke is based on the definition used in the trial of ORG 10172 in Acute Stroke Treatment (TOAST) [5]. Cryptogenic stroke (or “stroke of undetermined etiology” in TOAST terminology) is defined as an ischemic brain infarction not attributable to large-artery atherosclerosis, small artery disease, or cardioembolism despite a standard vascular, cardiac, and serologic evaluation (Table 1). Emerging data suggest that active cancer is an important underlying cause of ischemic stroke in individuals with cryptogenic stroke, with unique pathophysiology and treatment considerations [6]. Several large studies have demonstrated an increased risk of ischemic stroke in patients with new cancer diagnoses compared to matched controls [7, 8]. It is also increasingly recognized that stroke can precede cancer diagnosis by several months indicating that stroke may be the first manifestation of underlying cancer [9, 10]. Up to 10% of individuals with cryptogenic ischemic stroke are diagnosed with cancer within one year, which is similar to the incidence of occult cancer in individuals with unprovoked (no identifiable major risk factors) thromboembolism (VTE) [10–12]. However, compared to the extensive literature on cancer associated VTE, research on cancer associated stroke is more limited [11]. Although experts endorse consideration of underlying occult cancer as an etiology of cryptogenic stroke [6, 13, 14], specific recommendations are lacking and no advice is given in current guidelines [15–20]. Given the uncertainty about the extent and type of existing literature regarding screening for occult cancer in patients with ischemic stroke, we will map the available evidence in this scoping review in order to identify current knowledge gaps prior to undertaking a systematic review.

thumbnail
Download:
Table 1. Routine workup according to TOAST criteria for stroke of undetermined etiology [13].

https://doi.org/10.1371/journal.pone.0289048.t001

Methods

This scoping review will be conducted according to the methodology proposed by Arksey and O’Malley [21, 22] which consists of nine stages as follows: 1) identify the research question(s); 2) develop the inclusion criteria; 3) describe the planned approach to evidence searching, selection, data extraction, and presentation; 4) search for the evidence; 5) select the evidence; 6) extract the evidence; 7) analyze the evidence; 8) present the results; 9) summarize the evidence in relation to the purpose of the review, making conclusions and noting any implications of the findings. This study is registered with the Open Science Framework (https://osf.io/3h95q). The results will be reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR).

Research question

In patients with cryptogenic ischemic stroke, have occult cancer screening strategies been evaluated and, if so, what tests have been used and what is the clinical value in terms of positive and negative predictive value?

Inclusion and exclusion criteria

All articles that describe strategies for detecting occult cancers in adult patients with ischemic stroke (including, but not limited to, imaging tests, laboratory investigations, clinical assessments) will be assessed. Eligible articles include expert opinions, guidelines, narrative and systematic reviews, case-series and case-reports, conference abstracts, observational and randomized studies. Non-English reports, animal studies, studies limited to intracerebral hemorrhage, studies in patients with known cancers, studies on cardioembolic ischemic stroke (including fibroelastoma, atrial myxoma, and non-bacterial thrombotic endocarditis), and studies without details about screening strategies will be excluded. The reference lists of articles selected for full-text review will also be reviewed for potentially eligible studies that were not captured by the search.

Search strategy and information sources

The search strategy was developed by a health sciences librarian (VL) and peer-reviewed by an independent health sciences librarian from the University of Ottawa (Tables 2–5) [23]. MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and Scopus were searched with no limits to language or publication date using appropriate subject headings and keywords (see S1 Checklist for full search details). The main search concepts comprise of terms related to ischemic stroke and cancer screening. Search results were exported to Covidence (Melbourne, Australia) and duplicates were eliminated using the platform’s duplicate identification feature.

thumbnail
Download:
Table 2. Medline (Ovid) search strategy.

https://doi.org/10.1371/journal.pone.0289048.t002

thumbnail
Download:
Table 3. Embase (Ovid) search strategy.

https://doi.org/10.1371/journal.pone.0289048.t003

thumbnail
Download:
Table 4. CINAHL (EBSCO) search strategy.

https://doi.org/10.1371/journal.pone.0289048.t004

thumbnail
Download:
Table 5. Scopus search strategy.

https://doi.org/10.1371/journal.pone.0289048.t005

Article selection

We will use a two-stage study selection of title and abstract screening, followed by full-text review, to be completed by two independent reviewers [24]. Disagreements will be resolved by discussion, or involvement of a third reviewer if consensus cannot be reached. A PRISMA flow diagram will be used to summarize the process of article selection.

Data extraction and management

For studies that meet the inclusion criteria, relevant data will be extracted and captured using a standardized data extraction form. Specific data to be collected are shown in Table 6.

thumbnail
Download:
Table 6. Data included in the standardized data extraction form.

https://doi.org/10.1371/journal.pone.0289048.t006

Conclusion

The objective of the scoping review described in this protocol is to summarize the available evidence on screening strategies to detect occult cancer in individuals with ischemic stroke. We anticipate that this review will summarize the type of tests and/or strategies that are used in clinical practice and provide preliminary evidence about their utility, but there will be heterogeneity due to existing knowledge gaps about the optimal strategy. Information gathered from this review will also help to guide the development of future clinical trials on screening strategies for occult cancer in individuals with ischemic stroke.

Supporting information

S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: Recommended items to address in a systematic review protocol*.

https://doi.org/10.1371/journal.pone.0289048.s001

(DOC)

Acknowledgments

We thank Victoria Cole, BScN, MScN, MIS (Health Sciences Library, University of Ottawa) for peer review of the MEDLINE search strategy.

References

  1. 1. Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. pmid:34487721
  2. 2. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–e743. pmid:33501848
  3. 3. Ekker MS, Boot EM, Singhal AB, Tan KS, Debette S, Tuladhar AM, et al. Epidemiology, aetiology, and management of ischaemic stroke in young adults. Lancet Neurol. 2018;17(9):790–801. pmid:30129475
  4. 4. Boot E, Ekker MS, Putaala J, Kittner S, De Leeuw FE, Tuladhar AM. Ischaemic stroke in young adults: a global perspective. J Neurol Neurosurg Psychiatry. 2020;91(4):411–7. pmid:32015089
  5. 5. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. pmid:7678184
  6. 6. Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and Embolic Stroke of Undetermined Source. Stroke. 2021;52(3):1121–30. pmid:33504187
  7. 7. Mulder FI, Horvath-Puho E, van Es N, Pedersen L, Buller HR, Botker HE, et al. Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study. JACC CardioOncol. 2021;3(2):205–18.
  8. 8. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70(8):926–38.
  9. 9. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133(8):781–9. pmid:30578253
  10. 10. Wei YC, Chen KF, Wu CL, Lee TW, Liu CH, Shyu YC, et al. Stroke Rate Increases Around the Time of Cancer Diagnosis. Front Neurol. 2019;10:579. pmid:31231302
  11. 11. D’Astous J, Carrier M. Screening for Occult Cancer in Patients with Venous Thromboembolism. J Clin Med. 2020;9(8). pmid:32726911
  12. 12. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149(5):323–33. pmid:18765702
  13. 13. May JE, Moll S. Unexplained arterial thrombosis: approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2021;2021(1):76–84. pmid:34889390
  14. 14. Saver JL. Cryptogenic Stroke. N Engl J Med. 2016;375(11):e26.
  15. 15. Ahmed N, Audebert H, Turc G, Cordonnier C, Christensen H, Sacco S, et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018. Eur Stroke J. 2019;4(4):307–17. pmid:31903429
  16. 16. Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, et al. Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care, 6th Edition, Update 2018. Int J Stroke. 2018;13(9):949–84. pmid:30021503
  17. 17. Dong Q, Dong Y, Liu L, Xu A, Zhang Y, Zheng H, et al. The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke. Stroke Vasc Neurol. 2017;2(3):147–59. pmid:28989804
  18. 18. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467. pmid:34024117
  19. 19. Oliveira-Filho J, Martins SC, Pontes-Neto OM, Longo A, Evaristo EF, Carvalho JJ, et al. Guidelines for acute ischemic stroke treatment: part I. Arq Neuropsiquiatr. 2012;70(8):621–9. pmid:22899035
  20. 20. Rudd AG, Bowen A, Young GR, James MA. The latest national clinical guideline for stroke. Clin Med (Lond). 2017;17(2):154–5. pmid:28365628
  21. 21. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. pmid:20854677
  22. 22. Peters MDJ, Godfrey C, McInerney P, Khalil H, Larsen P, Marnie C, et al. Best practice guidance and reporting items for the development of scoping review protocols. JBI Evid Synth. 2022;20(4):953–68. pmid:35102103
  23. 23. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40–6.
  24. 24. Halas G, Schultz AS, Rothney J, Goertzen L, Wener P, Katz A. A scoping review protocol to map the research foci trends in tobacco control over the last decade. BMJ Open. 2015;5(1):e006643. pmid:25631312